SciClone Pharmaceuticals (Holdings) (HKSE:06600) Change In Payables And Accrued Expense : HK$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Change In Payables And Accrued Expense?

SciClone Pharmaceuticals (Holdings)'s Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was HK$0 Mil. It means SciClone Pharmaceuticals (Holdings)'s Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

SciClone Pharmaceuticals (Holdings)'s Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was HK$0 Mil. It means SciClone Pharmaceuticals (Holdings)'s Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

SciClone Pharmaceuticals (Holdings) Change In Payables And Accrued Expense Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Change In Payables And Accrued Expense Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial						-	-	-	-	-

SciClone Pharmaceuticals (Holdings) Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

SciClone Pharmaceuticals (Holdings) Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Change In Payables And Accrued Expense

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines